Zobrazeno 1 - 10
of 298
pro vyhledávání: '"Robert A. Dillman"'
Autor:
Ian J. Cohen, Chloe Beddingfield, Robert Chancia, Gina DiBraccio, Matthew Hedman, Shannon MacKenzie, Barry Mauk, Kunio M. Sayanagi, Krista M. Soderlund, Elizabeth Turtle, Caitlin Ahrens, Christopher S. Arridge, Shawn M. Brooks, Emma Bunce, Sebastien Charnoz, Athena Coustenis, Robert A. Dillman, Soumyo Dutta, Leigh N. Fletcher, Rebecca Harbison, Ravit Helled, Richard Holme, Lauren Jozwiak, Yasumasa Kasaba, Peter Kollmann, Statia Luszcz-Cook, Kathleen Mandt, Olivier Mousis, Alessandro Mura, Go Murakami, Marzia Parisi, Abigail Rymer, Sabine Stanley, Katrin Stephan, Ronald J. Vervack, Jr., Michael H. Wong, Peter Wurz
Publikováno v:
The Planetary Science Journal, Vol 3, Iss 3, p 58 (2022)
Current knowledge of the Uranian system is limited to observations from the flyby of Voyager 2 and limited remote observations. However, Uranus remains a highly compelling scientific target due to the unique properties of many aspects of the planet i
Externí odkaz:
https://doaj.org/article/d5bb6ff2aa5b4409ab0ed75cac237df5
Autor:
Gabriel I. Nistor, Robert O. Dillman
Publikováno v:
Journal of Translational Medicine, Vol 18, Iss 1, Pp 1-19 (2020)
Abstract Background In a randomized phase II trial conducted in patients with metastatic melanoma, patient-specific autologous dendritic cell vaccines (DCV) were associated with longer survival than autologous tumor cell vaccines (TCV). Both vaccines
Externí odkaz:
https://doaj.org/article/a8b00cccaccb4b819e4d9ee0fd18533a
Publikováno v:
Human Vaccines & Immunotherapeutics.
Autor:
Robert O. Dillman, Andrew N. Cornforth, Gabriel I. Nistor, Edward F. McClay, Thomas T. Amatruda, Carol Depriest
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-10 (2018)
Abstract Background Despite improved survival following checkpoint inhibitors, there is still a potential role for anti-cancer therapeutic vaccines. Because of biological heterogeneity and neoantigens resulting from each patient’s mutanome, autolog
Externí odkaz:
https://doaj.org/article/7fc4f57ae882440fb8bc9d87219302a6
Autor:
Daniela A. Bota, Thomas H. Taylor, David E. Piccioni, Christopher M. Duma, Renato V. LaRocca, Santosh Kesari, Jose A. Carrillo, Mehrdad Abedi, Robert D. Aiken, Frank P. K. Hsu, Xiao-Tang Kong, Candace Hsieh, Peter G. Bota, Gabriel I. Nistor, Hans S. Keirstead, Robert O. Dillman
Publikováno v:
Journal of experimental & clinical cancer research : CR, vol 41, iss 1
Background Vaccine immunotherapy may improve survival in Glioblastoma (GBM). A multicenter phase II trial was designed to determine: (1) the success rate of manufacturing the Aivita GBM vaccine (AV-GBM-1), (2) Adverse Events (AE) associated with AV-G
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d452687f27f51d3fa6d821c2d61a207
https://doi.org/10.21203/rs.3.rs-2117699/v1
https://doi.org/10.21203/rs.3.rs-2117699/v1
Autor:
Daniela A, Bota, Thomas H, Taylor, David E, Piccioni, Christopher M, Duma, Renato V, LaRocca, Santosh, Kesari, Jose A, Carrillo, Mehrdad, Abedi, Robert D, Aiken, Frank P K, Hsu, Xiao-Tang, Kong, Candace, Hsieh, Peter G, Bota, Gabriel I, Nistor, Hans S, Keirstead, Robert O, Dillman
Publikováno v:
Journal of experimentalclinical cancer research : CR. 41(1)
Vaccine immunotherapy may improve survival in Glioblastoma (GBM). A multicenter phase II trial was designed to determine: (1) the success rate of manufacturing the Aivita GBM vaccine (AV-GBM-1), (2) Adverse Events (AE) associated with AV-GBM-1 admini
Autor:
Gabriel I. Nistor, Robert O. Dillman, Rockelle M. Robles, James L. Langford, Aleksandra J. Poole, Muchlis A. U. Sofro, Yetty M. Nency, Jonny Jonny, Martina L. Yana, Mahammad Karyana, Endang S. Lestari, Ria Triwardhani, Mujahidah Mujahidah, Retty K. Sari, Nur A. Soetojo, Djoko Wibisono, Daniel Tjen, Taruna Ikrar, Gregory Sarkissian, Haryono Winarta, Terawan A. Putranto, Hans S. Keirstead
Publikováno v:
Human vaccinesimmunotherapeutics. 18(6)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a world-wide pandemic. Internationally, because of availability, accessibility, and distribution issues, there is a need for additional vaccines. This study aimed to: establish t
Autor:
Robert Owen Dillman, Candace Hsieh
Publikováno v:
Biomedicines, Vol 7, Iss 4, p 80 (2019)
Encouraging survival was observed in single arm and randomized phase 2 trials of patient-specific dendritic cell vaccines presenting autologous tumor antigens from autologous cancer cells that were derived from surgically resected metastases whose ce
Externí odkaz:
https://doaj.org/article/e50d2c18007e48a2b2b5f77864699630
Autor:
Stephen J. Horan, David H. Atkinson, Angela L. Bowes, Archit Arora, Sarag J. Saikia, Thomas R. Spilker, Robert A. Dillman, Kunio M. Sayanagi
Publikováno v:
Journal of Spacecraft and Rockets. 58:697-707
In situ atmospheric measurements are a high priority for any future Flagship mission to the Ice Giants; however, most current mission concepts only include a single atmospheric entry probe in their...
Autor:
Renato V. LaRocca, Robert O Dillman, Gabriel Nistor, Mehrdad Abedi, Jose Carrillo, Thomas H. Taylor, Frank P.K. Hsu, Christopher Duma, Robert Aiken, Santosh Kesari, David Piccioni, Candace Hsieh, Xiao-Tang Kong, Daniela A. Bota
Publikováno v:
Neuro Oncol
Neuro-Oncology, vol 23, iss Supplement_6
Neuro-Oncology, vol 23, iss Supplement_6
In primary glioblastoma (GBM), overall survival (OS) is poor despite standard aggressive therapy. Adjunctive AV-GBM-1 vaccine immunotherapy may improve OS. In this multi-institutional phase II trial, key eligibility criteria for intent-to-treat (ITT)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6bc93a34830b30cc812ef84e13606b8
https://europepmc.org/articles/PMC8598812/
https://europepmc.org/articles/PMC8598812/